Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Keryx Biopharmaceuticals Surges on Prospects for Kidney Drug


The biotech company says a treatment for kidney failure patients met its goal in a company study. CEO Bentsur says Keryx will seek US and European approval of Zerenex in the second quarter.

Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) are surging after the company said its experimental drug for kidney dialysis patients met its goal for effectiveness in a late-stage study. Keryx plans to seek US and European approval for the drug in the second quarter.

Shares of Keryx jumped more than 40% to $4.82 in late-morning trading Monday. The stock is up 56% over the past 12 months.

The New York-based company said its drug Zerenex met its study target for lowering phosphate levels in the blood of patients with kidney failure. Patients on Keryx's drug showed a statistically significant reduction compared with those trial participants who were given a placebo. (As kidney function deteriorates, blood phosphate levels rise.)

"There is no question that Zerenex delivered strong data today," Keryx CEO Ron Bentsur told analysts and investors on a conference call Monday morning. "We believe the data presented today clearly suggests that Zerenex has the potential to become the market leader" for this type of treatment.

The market for so-called phosphate binders, drugs designed to address this problem in kidney patients, is about $1.5 billion in annual sales, says Burrill Institutional Research analyst Reni Benjamin.

Sanofi's (NYSE:SNY) Renagel and Renvela drugs make up about half that market now, Benjamin says. Impax Laboratories (NASDAQ:IPXL) is licensed to sell generic versions of the drugs following a legal settlement with Sanofi announced last year.

"We believe Keryx can compete quite favorably once generics enter the marketplace in 2014," Benjamin says in a recent note.

Keryx's drug also met secondary goals of improving iron levels in patients and reducing the need for intravenous delivery of the mineral. Bentsur says the positive results for the secondary endpoints further distinguishes Zerenex from other similar medicines.

In the US alone, there are almost a half million patients with end-stage renal disease -- complete or nearly complete kidney failure -- and that number is going to rise about 60% by 2020, according to figures cited by Keryx. More than 350,000 kidney failure patients now require dialysis, Keryx says.

Full results of the Keryx study will be available at an upcoming medical meeting.

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos